Some Stocks That May Be Hidden Gems
While most investors try to follow bubbles or pick over popular stocks for a little bit of profit, these undervalued companies may be poised for a bit of growth.
stem cell research
Inside Wall Street: This Tiny Stem Cell Biotech Has the Vatican's Backing
Stem cell research is still too hot for most investors, but NeoStem is starting to change that, thanks to some unexpected events. Among them are the Catholic Church's surprising embrace of NeoStem's research and NeoStem's foothold in China's vast health care market.
World's First Stem Cell Clinical Trial to Treat Stroke Begins in U.K.
The first stroke patient ever to be treated with stem cell therapy has reportedly been discharged from the hospital and is doing well. Stem-cell technology is viewed as a highly promising new area of medical science, but it is also highly controversial because of the source of the cells.
Legal Briefing: Supreme Court Considering Music File-Sharing Case
In today's legal news, the Supreme Court has expressed interest in a case involving a teenager's illegal music file-sharing, the legal battle over stem cell research has already pushed some scientists to other fields, and a third woman has alleged that a Wisconsin DA harassed her with sexual text messages.
Legal Briefing: More Plead Guilty to Cheating Municipalities
In Friday's legal news, two more people pleaded guilty in a bid-rigging scheme that involved deals with some 160 U.S. municipalities; California public schools are being sued for charging fees for various school essentials; and Alaska is suing the U.S. government for 'banning' offshore drilling.
Potential Paralysis Cure Pushes Shares of StemCells Up
StemCells Inc. shares jumped some 14% after the company reported new preclinical data showing its proprietary human neural stem cells restore lost motor function in mice long after their spinal cord injuries.
Geron to Test Embryonic Stem-Cell Therapy After FDA Lifts Clinical Hold; Shares Soar
Pharmaceutical company Geron announced that the U.S. Food and Drug Administration has lifted the clinical hold it had placed on the company's new drug application, allowing it to proceed with a clinical trial of GRNOPC1 in patients suffering from acute spinal cord injury.
